Advanced search
Publication Cover
Scandinavian Journal of Urology Volume 48, 2014 - Issue 4
Journal homepage
259
Views
7
CrossRef citations to date
0
Altmetric
Original Article

Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre

Trine Honnens De LichtenbergDepartment of Urology, Rigshospitalet, Copenhagen, Denmark
,
Gregers G. HermannDepartment of Urology, Rigshospitalet, Copenhagen, Denmark;Department of Urology, Frederiksberg Hospital, Frederiksberg, DenmarkCorrespondence[email protected]
,
Mikael RørthDepartment of Oncology, Rigshospitalet, Copenhagen, Denmark
,
Mari-Janne Højer LarsenDepartment of Urology, Rigshospitalet, Copenhagen, Denmark
,
Zahra MansourvarDepartment of Biostatistics, University of Copenhagen, Copenhagen, Denmark
,
Mette L. HolmDepartment of Urology, Rigshospitalet, Copenhagen, Denmark
&
Thomas ScheikeDepartment of Biostatistics, University of Copenhagen, Copenhagen, Denmark
 show all
Pages 379-386 | Received 06 May 2013, Accepted 12 Dec 2013, Published online: 12 Feb 2014

References

  • Geertsen PF, Hermann GG, Claesson MH, Steven K, Zeuthen J, von der Maase H. [Interleukin-2 based immunotherapy of cancer]. Ugeskr Laeger 1990;152:3513–17.
  • McDermott DF. Immunotherapy of metastatic renal cell carcinoma. Cancer 2009;115:2298–305.
  • Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int 2011;108:1556–63.
  • Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584–90.
  • Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530–40.
  • Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27:5794–9.
  • Gore ME, Griffin CL, Hancock B, Patel PM, Pyle L, Aitchison M, et al. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet 2010;375:641–8.
  • Atzpodien J, Kirchner H, Illiger HJ, Metzner B, Ukena D, Schott H, et al. IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 2001;85:1130–6.
  • Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–16.
  • Sobin L, Gospodarowich M, Wittekind C. AJCC staging manual. 7th ed. Philadelphia, PA: Springer; 2009.
  • van de Wiel MA, Berkhof J, van Wieringen WN. Testing the prediction error difference between 2 predictors. Biostatistics 2009;10:550–60.
  • Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009;10:757–63.
  • Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345:1655–9.
  • Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358:966–70.
  • Flanigan RC, Mickisch G, Sylvester R, Tangen C, van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:1071–6.
  • Chowdhury S, Harper PG, Choueiri TK. The role of cytoreductive nephrectomy for renal cell carcinoma in the era of targeted therapy. Nat Clin Pract Oncol 2008;5:698–9.
  • Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115–24.
  • Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, et al.et al. II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:1280–9.
  • Harshman LC, Xie W, Bjarnason GA, Knox JJ, Mackenzie M, Wood L, et al. Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol 2012;13:927–35.
  • Piltz S, Meimarakis G, Wichmann MW, Hatz R, Schildberg FW, Fuerst H. Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann Thorac Surg 2002;73:1082–7.
  • Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J Clin Oncol 1998;16:2261–6.
  • Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 2011;117:2873–82.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.